ArticleRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology2011
Early CT and FDG-metabolic tumour volume changes show a significant correlation with survival in stage I-III small cell lung cancer: a hypothesis generating study.
Article in Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 49 citations in OpenAlex.
- Optimal FDG PET/CT volumetric parameters for risk stratification in patients with locally advanced non-small cell lung cancer: results from the ACRIN 6668/RTOG 0235 trial.European journal of nuclear medicine and molecular imaging · 2017Trial
- FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2).European journal of nuclear medicine and molecular imaging · 2014Trial
- [18F]FDG-PET/CT-based evaluation of tumor response kinetics during induction chemotherapy and concurrent radiochemotherapy in stage II - III small-cell lung cancer.European journal of nuclear medicine and molecular imaging · 2026Article
- Prognostic Value ofDiagnostics (Basel, Switzerland) · 2021Review
- Metabolic tumor volume predicts overall survival in patients with primary pulmonary lymphoepithelioma-like carcinoma.Oncology letters · 2019Article
- Review
- Use of Positron Emission Tomography/Computed Tomography in Radiation Treatment Planning for Lung Cancer.Molecular imaging and radionuclide therapy · 2016Article
- Present and future roles of FDG-PET/CT imaging in the management of lung cancer.Japanese journal of radiology · 2016Review
- Article
- The role of texture analysis in imaging as an outcome predictor and potential tool in radiotherapy treatment planning.The British journal of radiology · 2014Review
- Positron emission tomography/computerized tomography in lung cancer.Quantitative imaging in medicine and surgery · 2014Review
- Temporal analysis of intratumoral metabolic heterogeneity characterized by textural features in cervical cancer.European journal of nuclear medicine and molecular imaging · 2013Article
- Prognostic implications of volume-based measurements on FDG PET/CT in stage III non-small-cell lung cancer after induction chemotherapy.European journal of nuclear medicine and molecular imaging · 2013Article
- Application of FDG-PET/CT in Radiation Oncology.Frontiers in oncology · 2013Article
- Predictive and prognostic value of metabolic tumour volume and total lesion glycolysis in solid tumours.European journal of nuclear medicine and molecular imaging · 2013Article
- Predicting outcomes in radiation oncology--multifactorial decision support systems.Nature reviews. Clinical oncology · 2013Review
- Response assessment using 18F-FDG PET early in the course of radiotherapy correlates with survival in advanced-stage non-small cell lung cancer.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2012Article
- Use of FDG-PET in Radiation Treatment Planning for Thoracic Cancers.International journal of molecular imaging · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundMany patients with stage I-III small cell lung cancer (SCLC) experience disease progression short after the completion of concurrent chemoradiotherapy (CRT). The purpose of the current study was to evaluate whether CT or FDG metabolic response early after the start of chemotherapy, but before the beginning of chest RT, is predictive for survival in SCLC.
methodsFifteen stage I-III SCLC patients treated with concurrent CRT with an FDG-PET and CT scan available before the start of chemotherapy and after or during the first cycle of chemotherapy, but before the start of radiotherapy, were selected. The metabolic volume (MV) was defined both within the primary tumour and in the involved nodal stations using the 40% (MV40) and 50% (MV50) threshold of the maximum SUV. Metabolic and CT response was assessed by the relative change in MV and CT volume, respectively, between both time points. The association between response and overall survival (OS) was analysed by univariate cox regression analysis. The minimum follow-up was 18 months.
resultsReductions in MV40 and MV50 were -36±38% (126.4 to 68.7cm(3)) and -44±38% (90.2 to 27.8cm(3)), respectively. The median CT volume reduction was -40±64% (190.6 to 113.8cm(3)). MV40 and MV50 changes showed a significant association with survival (HR=1.02, 95% CI: 1.00-1.04 (p=0.042); HR=1.02, 95% CI: 1.00-1.04 (p=0.048), respectively), indicating a 2% increase in survival probability for 1% reduction in metabolic volume. The CT volume change was also significantly correlated with survival (HR=1.01, 95% CI: 1.00-1.03, p=0.007).
conclusionsThis hypothesis generating study shows that both the early CT and the MV changes show a significant correlation with survival in SCLC. A prospective study is planned in a larger patient cohort to allow multivariate analysis, with the final aim to select patients early during treatment that could benefit from dose intensification or alternative treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.